Claims for Patent: 5,028,432

Summary for Patent: 5,028,432

Title:	Pharmaceutical capsules containing panetidine
Abstract:	The invention relates to a pharmaceutical composition in the form of a gelatin capsules consisting of a filling containing as active ingredient ranitidine or a physiologically acceptable salt thereof surrounded by a gelatin shell. The filling is formulated based on a non-aqueous matrix consisting of at least one fatty acid glyceride and/or mineral oil or paraffin. Preferably the matrix contains at least one surfactant. The matrix is essentially hydrophobic in character but is also sufficiently hydrophilic to permit dispersion and dissolution of the capsule filling in the gastrointenstinal tract.
Inventor(s):	Chopra; Sham K. (Bramalea, CA), Makadia; Tribhovan T. (Mississauga, CA)
Assignee:	Glaxo Canada, Inc. (CA)
Application Number:	07/482,903
Patent Claims:	1. A pharmaceutical composition in the form of gelatin capsules comprising a filling containing as active ingredient ranitidine or a physiologically acceptable salt thereof surrounded by a gelatin shell, said filling being based on a non-aqueous matrix consisting essentially of at least one fatty acid glyceride and/or mineral oil or paraffin. 2. A pharmaceutical composition according to claim 1 in which said matrix contains at least one surfactant. 3. A pharmaceutical composition according to claim 2 in which said matrix consisting essentially of a mixture of fatty acid glycerides and/or mineral oils or paraffins in which at least one component of the mixture possesses surfactant properties. 4. A pharmaceutical composition according to claim 2 in which said surfactant is lecithin. 5. A pharmaceutical composition according to claim 1 in which said gelatin shell is a soft gelatin shell. 6. A pharmaceutical composition according to claim 1 in which said filling contains 30 to 70% (w/w) ranitidine in the form of either free base or physiologically acceptable salt. 7. A pharmaceutical composition according to claim 1 containing ranitidine in the form of ranitidine hydrochloride. 8. A pharmaceutical composition in the form of gelatin capsules consisting essentially of a filling containing as active ingredient ranitidine or a physiologically acceptable salt thereof surrounded by a gelatin shell, said filling being based on a non-aqueous matrix comprising a first oily excipient which is a mixture of glycerides of medium chain fatty acids and a second oily excipient which is a mixture of glycerides of long chain fatty acids. 9. A pharmaceutical composition according to claim 8 in which said first oily excipient is a mixture of triglycerides of C.sub.8 -C.sub.10 fatty acids and said second oily excipient is a mixture of mono-, di-, and/or triglycerides of C.sub.12 -C.sub.18 fatty acids. 10. A pharmaceutical composition according to claim 9 in which said first oily excipient comprises 20% to 60% (w/w) of said filling and said second oily excipient comprises 5 to 35% (w/w) of said filling. 11. A pharmaceutical composition according to claim 8 in which said gelatin shell is a soft gelatin shell. 12. A pharmaceutical composition according to claim 8 in which said filling contains 30 to 70% (w/w) ranitidine in the form of either free base or physiologically acceptable salt. 13. A pharmaceutical composition according to claim 8 containing ranitidine in the form of ranitidine hydrochloride. 14. A pharmaceutical composition according to claim 8 containing ranitidine hydrochloride as active ingredient in which said ranitidine hydrochloride comprises 45% to 55% (w/w) of said filling and said filling is based on a non-aqueous matrix consisting essentially of a first oily excipient which is a mixture of triglycerides of C.sub.8 -C.sub.10 fatty acids and comprises 30% to 40% (w/w) of said filling, and a second oily excipient which is a mixture of mono-, di- and/or triglycerides of C.sub.12 -C.sub.18 fatty acids and comprises 10% to 25% (w/w) of said filling. 15. A composition suitable for use as a filling for gelatin capsules comprising ranitidine or a physiologically acceptable salt thereof and a non-aqueous matrix consisting essentially of at least one fatty acid glyceride and/or mineral oil or paraffin. 16. A non-aqueous pharmaceutical composition comprising ranitidine or a physiologically acceptable salt thereof and a non-aqueous matrix consisting essentially of at least one fatty acid glyceride and/or mineral oil or paraffin together with a pharmaceutically acceptable non-aqueous vehicle.